TY - JOUR
T1 - Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer
AU - Arslan, Nuri
AU - Miller, Tom R.
AU - Dehdashti, Farrokh
AU - Battafarano, Richard J.
AU - Siegel, Barry A.
PY - 2002
Y1 - 2002
N2 - Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV peak), average SUV (SUVave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.
AB - Purpose: This work evaluates positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in assessing response to therapy in patients with esophageal cancer. Procedures: Twenty-four patients underwent FDG-PET before (pre-Rx) and after (post-Rx) chemoradiation therapy; 20 then underwent esophagectomy. The response of the primary tumors was visually assessed, and tumor volume, peak tumor standardized uptake value (SUV peak), average SUV (SUVave), and total lesion glycolysis were determined pre-treatment and post-treatment. Patients were divided into groups according to the absence (Group A) or presence (Group B) of residual tumor after neoadjuvant therapy. Results: Among the quantitative PET parameters for Group A (n = 6) and Group B (n = 18), only change in tumor volume identified complete responders. Quantitative PET indices were not different in patients with or without post-Rx esophagitis. Conclusions: The change in tumor volume identifies patients with complete response to neoadjuvant therapy, and quantitative evaluation of the primary tumor cannot separate post-Rx inflammation from residual tumor.
KW - Esophageal cancer
KW - FDG-PET
KW - Response evaluation
UR - http://www.scopus.com/inward/record.url?scp=0036660972&partnerID=8YFLogxK
U2 - 10.1016/S1536-1632(02)00011-2
DO - 10.1016/S1536-1632(02)00011-2
M3 - Article
C2 - 14537121
AN - SCOPUS:0036660972
SN - 1536-1632
VL - 4
SP - 301
EP - 310
JO - Molecular Imaging and Biology
JF - Molecular Imaging and Biology
IS - 4
ER -